Expert Chaslau Koniukh
  • Companies
  • Global investment
  • Investors
  • Terminology
  • Economy
  • Stock Market
  • World exchanges
  • Tech and Marketing
RUSNANO company
Stock Market

RUSNANO’s subsidiary Atea Pharmaceuticals is listed on the New York Stock Exchange

07.07.2021
2 min read

RUSNANO subsidiary conducted an initial public offering

Atea Pharmaceuticals, a subsidiary of RUSNANO, made its initial public offering on the New York Stock Exchange. The company’s sphere of activity is antiviral therapy research and development of new generation medical products. One of the company’s areas of activity is the study of coronavirus COVID-19 and the vaccine against it.
During the IPO Atea Pharmaceuticals placed 12.5 million shares on the stock exchange, the price of one security was $24. The total amount came out to 300 million dollars, and the value of the company was estimated at about 1.9 billion dollars. The first trades after the placement brought a 25 percent increase in the share price. The IPO procedure was carried out with the participation of such well-known firms as J.P. Morgan, William Blair, Morgan Stanley and others.
The funds received during the placement are planned to be used for development of clinical trials and improvement of operational processes. Now the main subject of development is the creation of a drug that fights the virus type SARS-CoV-2, which caused the pandemic last year. The specialists of the company have already developed a drug that is under clinical trials. Now it is at the second stage of testing. In addition to this direction, Atea is studying the mechanisms of treatment of hepatitis C, dengue fever, and is creating effective drugs against these diseases.

RUSNANO company

Atea is part of RosMedInvest’s portfolio, the latter acquired the developer of the drugs in 2014 during Round A. The company’s shareholders are also investment funds, including JPM Partners, ABG-ATEAB Limited and others. Despite the fact that Atea has placed its shares on the stock exchange, RMI does not plan to carry out an IPO.
It should be noted that investments in Atea have become an example of classic financial success. RosMedInvest started financing at the initial stage of the company’s formation. As a result, Atea, with the support of RMI, has gone all the way to development. Now all the company’s efforts are focused on the development of anti-virus drugs, and there are already the first positive results. However, the most difficult thing for the company is ahead – it is necessary to prove the effectiveness of drugs, and first of all drugs against COVID-19. The third phase of testing should begin in the second half of the year. For this purpose, Atea is preparing an extensive scientific and clinical base, which will enable it to carry out all necessary research and confirm the benefit of the drug in treating the virus.
As soon as a pandemic was declared in the world, Atea urgently re-qualified its capacity to develop a drug against COVID-19. Between May and October, the company managed to attract a new round of investment, which took place in two tranches. In total, 215 million dollars were received, and already in May, Atea presented the first results of its development.

Tags: Stock Market
0
Previous Post How much the Mexico's economy has suffered: an overview of the situation Next Post World Gold Council analysts: what are the drivers of gold market growth

You Might Also Like

Gold_Russia
Stock Market
Gold reserves in Russia are declining: the factors that affect the movement of the asset
25.09.2021
Bonds with a negative yield
Stock Market
Great Britain started selling bonds with a negative yield
07.02.2021
Merck
Stock Market
Merck announced a deal with Imago
04.02.2023
PCR testing
Stock Market
A unique PCR test has been developed in Shanghai
03.05.2022
Blibli
Stock Market
Blibli platform raised $320 million in an IPO
26.12.2022
law on categorization of investors
Stock Market
Law on categorization of investors: review of changes in the document
18.04.2021

Recent Posts

  • 1Merck
    Merck announced a deal with Imago
    04.02.2023
  • 2slowdown in inflation in Germany
    Germany and other countries recorded a slowdown in inflation
    03.02.2023
  • 3John Craig Venter
    Who is John Craig Venter and his contribution to science
    02.02.2023
  • 4Mitsubishi
    Japanese Mitsubishi Corporation: history of creation
    01.02.2023
  • 5soft market
    Soft market: its impact on sellers and buyers
    31.01.2023

Popular Posts

  • Field of activity of the American Monsanto Company Corporation
  • Skolkovo analysts: the Russian energy market is suffering losses
  • Businessman Chuck Feeney: the man who gave the world Duty Free
  • Why the Federal Reserve System (FRS) refused to raise interest rates

Social media

Editor's Picks

Chaslau Koniukh
Analytics

American bankers from JPMorgan and Goldman Sachs advise to invest in gold: review by Chaslau Koniukh.

Spokesperson
17.08.2020
Expert Chaslau Koniukh
Analytics

Chaslau Koniukh on the analysts’ opinion on the key stake size change soon

Spokesperson
18.06.2020
expert Chaslau Koniukh
Analytics

Chaslau Koniukh: Internet trade market in Russia may reach 2.78 trillion rubles.

Spokesperson
30.05.2020
Will the U.S. oil shale industry be able to quickly recover from the crisis: A Review by Chaslau Koniukh
Analytics

Will the U.S. oil shale industry be able to quickly recover from the crisis: A Review by Chaslau Koniukh

Spokesperson
16.05.2020

Latest Posts

Merck
Merck announced a deal with Imago
04.02.2023
slowdown in inflation in Germany
Germany and other countries recorded a slowdown in inflation
03.02.2023
John Craig Venter
Who is John Craig Venter and his contribution to science
02.02.2023

Chaslau Koniukh

Expert Chaslau Koniukh

Chaslau Koniukh – an expert in marketing and project management, IT consulting, international investments, investor, financial analyst. A commodity trader, private consultant, entrepreneur, lecturer, author of several articles on the stock market.

Popular Posts

  • Field of activity of the American Monsanto Company Corporation
  • Skolkovo analysts: the Russian energy market is suffering losses
  • Businessman Chuck Feeney: the man who gave the world Duty Free
  • Why the Federal Reserve System (FRS) refused to raise interest rates
  • The success story of the company with the most expensive shares – Berkshire Hathaway Inc
Expert Chaslau Koniukh
  • Facebook
  • Twitter
  • Instagram
  • Biography

Chaslau Koniukh – an expert in marketing and project management, international investments, financial analyst.

Social media

Menu

  • Biography
  • Companies and corporations
  • Global investment
  • Investors and Entrepreneurs
  • Economy
  • Market terminology
  • Stock Market
  • World exchanges
  • Tech and Marketing
  • Analytics